RxDoctor Payments Data

Salvatore Bordonaro

Medical · Cleveland, OHNPI 1821337759

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,402 of the $5,059 with a category attached, or 67.2%. Astellas Pharma US Inc accounts for 81.6% of it on its own, with 8 other manufacturers making up the rest. 2025 is the largest year on record at $4,209, more than ten times the $220 reported in 2021.

$5,059in general payments, 2019–2025

Across 45 payments — averaging $112.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$4K
  • Rochester Medical Corporation$305
  • C. R. Bard, Inc. & Subsidiaries$208
  • Antares Pharma, Inc.$138
  • Otsuka America Pharmaceutical, Inc.$134
  • 180 Medical, Inc.$58
  • plus $89 from 3 others

What the payments were for

  • Consulting fees$3,40267%
  • Travel & lodging$52910%
  • Food & beverage$1,12822%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc10$4,127
Rochester Medical Corporation12$305
C. R. Bard, Inc. & Subsidiaries9$208
Antares Pharma, Inc.1$138
Otsuka America Pharmaceutical, Inc.7$134
180 Medical, Inc.2$58
BD2$53
Travere Therapeutics, Inc.1$20
Novartis1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,059 in reported general payments places this provider in the 85th percentile of 547 medical providers in Ohio.

See all medical providers in Ohio

Medicare billing

Part B allowed, 2024
$22,058
Medicare patients
250
Services billed
306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron14$6,962
Tamsulosin Hcl150$2,435
Estradiol13$834
Alfuzosin Hcl ErAlfuzosin Hcl18$780
Finasteride68$668
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav36$276
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst31$257
Doxycycline Monohydrate16$132
Cephalexin15$65
Prednisone13$21
PaxlovidNirmatrelvir/Ritonavir34$0

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$4,127$6,96214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 547 medical providers in Ohio.

Other medical in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →